{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:29:51Z","timestamp":1753892991094,"version":"3.41.2"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:00:00Z","timestamp":1734048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The incidence of gall bladder cancer (GBC), one of the most prevalent bile duct malignancies, differs with ethnicity and geographic location. To treat unresected GBC in the Chinese setting, this study aimed to assess the financial effectiveness of a combination of modified gemcitabine and oxaliplatin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data from a randomized controlled study in which individuals with metastatic GBC were treated with oxaliplatin and gemcitabine demonstrated improved survival. A Markov model is built to calculate the incremental cost\u2013benefit ratio (ICER) from the viewpoint of Chinese society on the basis of clinical symptoms and disease development. One-way certainty and probability sensitivity analyses are used to describe the uncertainty in the model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Compared with those of fluorouracil (FU) and folinic acid, the utility value of modified oxaliplatin combined with gemcitabine increased by 0.22QALY throughout the course of the 10-year simulation (FA). In a Chinese healthcare setting, the cost-effectiveness ratio (ICER) is $52765.59\/QALY, with a 0% chance of cost\u2013benefit at the WTP (willing-to-pay) level of $37697.00\/QALY. The ICERs predicted by sensitivity analysis were not significantly affected by cost variations related to the management of Grade 3\u20134 AEs, the diagnostics used, or hospitalization expenditures.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In a Chinese healthcare context, modified gemcitabine coupled with oxaliplatin (mGEMOX) is not a cost-effective treatment option for unresectable GBC.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2024.1432947","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T06:22:59Z","timestamp":1734070979000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Modification of gemcitabine with oxaliplatin in China for unresectable gallbladder cancer: a cost-effectiveness analysis"],"prefix":"10.3389","volume":"12","author":[{"given":"Zhaoyan","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangyuan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,13]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.hpb.2015.09.001","article-title":"Value of E-PASS models for predicting postoperative morbidity and mortality in resection of perihilar cholangiocarcinoma and gallbladder carcinoma","volume":"18","author":"Haga","year":"2016","journal-title":"HPB"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1056\/NEJM199104183241601","article-title":"A prospective analysis of 1518 laparoscopic cholecystectomies","volume":"324","author":"Club","year":"1991","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/sj.bjc.6605211","article-title":"Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study \u2013 the UK ABC-01 study","volume":"101","author":"Valle","year":"2009","journal-title":"Br J Cancer"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"526","DOI":"10.3349\/ymj.2005.46.4.526","article-title":"A phase II study of capecitabine combined with gemcitabine in patients with advanced gallbladder carcinoma","volume":"46","author":"Cho","year":"2005","journal-title":"Yonsei Med J"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1038\/sj.bjc.6601736","article-title":"A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer","volume":"90","author":"Doval","year":"2004","journal-title":"Br J Cancer"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00280-009-1055-0","article-title":"A phase II study of gemcitabine and oxaliplatin (Oxigem) in unresectable gall bladder cancer","volume":"65","author":"Sharma","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.annonc.2020.05.018","article-title":"Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced\/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial","volume":"31","author":"Demols","year":"2020","journal-title":"Ann Oncol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"4581","DOI":"10.1200\/JCO.2010.29.3605","article-title":"Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study","volume":"28","author":"Sharma","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.clinthera.2008.02.013","article-title":"Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland","volume":"30","author":"Purmonen","year":"2008","journal-title":"Clin Ther"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1177\/0272989X9401400107","article-title":"Determining transition probabilities","volume":"14","author":"Miller","year":"1994","journal-title":"Med Decis Mak"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"9996","DOI":"10.18632\/oncotarget.14310","article-title":"Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China","volume":"8","author":"Lu","year":"2017","journal-title":"Oncotarget"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1007\/s00520-020-05607-6","article-title":"Cost-effectiveness randomized clinical trial on the effect of photobiomodulation therapy for prevention of radiotherapy-induced severe oral mucositis in a Brazilian cancer hospital setting","volume":"29","author":"Lopes Martins","year":"2021","journal-title":"Support Care Cancer"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s12029-010-9242-0","article-title":"Cost-effectiveness of gemcitabine+cisplatin vs. gemcitabine monotherapy in advanced biliary tract cancer","volume":"43","author":"Roth","year":"2012","journal-title":"J Gastrointest Cancer"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1037\/cou0000757","article-title":"Interdependent stigma of seeking mental health services: examining a new scale across eight countries\/regions","volume":"71","author":"Vogel","year":"2024","journal-title":"J Couns Psychol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/hex.12498","article-title":"Health information sources for different types of information used by Chinese patients with cancer and their family caregivers","volume":"20","author":"Xie","year":"2017","journal-title":"Health Expect"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3390\/healthcare11060829","article-title":"Evaluation of the medical resource allocation: evidence from China","volume":"11","author":"Xi","year":"2023","journal-title":"Healthcare"},{"year":"2024","key":"ref17"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1007\/s12029-016-9885-6","article-title":"A cost-effectiveness analysis of gemcitabine plus cisplatin versus gemcitabine alone for treatment of advanced biliary tract Cancer in Japan","volume":"48","author":"Tsukiyama","year":"2017","journal-title":"J Gastrointest Cancer"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"871262","DOI":"10.3389\/fphar.2022.871262","article-title":"Cost-effectiveness analysis of Capecitabine plus Oxaliplatin versus gemcitabine plus Oxaliplatin as first-line therapy for advanced biliary tract cancers","volume":"13","author":"Chen","year":"2022","journal-title":"Front Pharmacol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1093\/annonc\/mdh351","article-title":"Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study","volume":"15","author":"Andr\u00e9","year":"2004","journal-title":"Ann Oncol"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2024.1432947\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T06:23:01Z","timestamp":1734070981000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2024.1432947\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,13]]},"references-count":20,"alternative-id":["10.3389\/fpubh.2024.1432947"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2024.1432947","relation":{},"ISSN":["2296-2565"],"issn-type":[{"type":"electronic","value":"2296-2565"}],"subject":[],"published":{"date-parts":[[2024,12,13]]},"article-number":"1432947"}}